August 8, 2011 – Phylonix today announced that it had been awarded a Phase II Small Business Innovation Research grant for $1,256,343 by the National Institute of General Medical Sciences. This grant supports development of a novel (patent pending) device for processing zebrafish. Although use of zebrafish for drug screening has increased dramatically during the last few decades, development of methods and instruments to streamline processing has not kept pace. This hand held device can be used to collect zebrafish embryos from breeding dishes and distribute them into containers such as microplates for drug treatment.
Phylonix, located in Cambridge, MA, is a Contract Research Organization developing and marketing patented, in vivo zebrafish-based assays, eZ-Screens™, for assessing drug candidates for cancers, central nervous system disorders, cardiovascular diseases, apoptosis, and organ toxicity. The company also offers services for target identification and validation. Partnerships are available for these services as well as for drug repositioning candidates that fail clinical trials for an initial indication. Services are tailored for several industry sectors including: agrochemicals, biotechnology, pharmaceuticals, nutraceuticals, environmental and other government agencies, as well as general safety liability. For information on licensing options contact Edward O’Lear, Vice President of Finance and Business Development at firstname.lastname@example.org or 617-441-6700 ex 302.<<Back to Home Page